我們已在上線！進一步了解

Harrow

HROW

市值 US$10.2億

27.28 USD

-1.47

5.11%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

27.41

+0.13

0.48%

1天

-5.11%

5天

-7.15%

1個月

-20.26%

3個月

-39.22%

6個月

-32.89%

今年迄今

-45.34%

1年

-28.06%

5年

165.11%

10年

739.38%

關於： Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

員工： 373

醫療保健藥品製造商－特殊及學名藥

新聞

正面

中性

負面

市場情緒 3個月

正面 20%

中性 66.7%

負面 13.3%

Zacks Investment Research

Do Options Traders Know Something About Harrow Stock We Don't?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Do Options Traders Know Something About Harrow Stock We Don't?

Harrow: Q3 Needs To Prove The Turnaround Is Real

Harrow remains a cautious Buy, despite a 20% stock decline and missed H1 revenue targets. HROW's full-year guidance demands a significant H2 performance, with Q3 and Q4 needing record-high revenues and positive EBITDA. Q3 has improved tailwinds: VEVYE gains payer coverage, IHEEZO benefits from better pricing and reimbursement, and TYRVAYA acquisition adds future potential.

Harrow: Q3 Needs To Prove The Turnaround Is Real

Harrow Closes Acquisition of TYRVAYA®

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise

Harrow Closes Acquisition of TYRVAYA®

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and American Academy of Ophthalmology's (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Harrow to Participate in Three Investor Conferences in September

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetings Date/Time: Wednesday, September 9, 2026, at 1:35 p.m.

Harrow to Participate in Three Investor Conferences in September

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Harrow is upgraded from Hold to a cautious Buy, driven by Q2 executional improvements and better visibility on operating leverage. VEVYE's revenue and economics have improved, while IHEEZO delivered record demand despite reimbursement headwinds, supporting the growth thesis. I model $490M in 2027 revenue and a 4.5x EV/sales multiple, yielding a $52 price target—about 33% upside from current levels.

Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.

Harrow Q2 Earnings Call Highlights

查看新聞排名

價格圖表採用Lightweight Charts™實作